Lupin contributes Rs 21 crore towards COVID-19 relief efforts

Image
ANI
Last Updated : Apr 11 2020 | 10:55 AM IST

Pharma major Lupin Ltd on Saturday announced a contribution of Rs 21 crore for relief efforts directed towards mitigating the COVID-19 crisis.

Lupin's Global Giving Programme comprises of three separate contributions made by its employees, the company and the promoter family.

Lupin's employees have contributed by giving two days of their individual salaries, together contributing a sum of Rs 5.5 crore to the Prime Minister's Citizen Assistance and Relief in Emergency Situations Fund (PM CARES Fund).

Lupin has matched an equal sum of Rs 5.5 crore for direct initiatives that the company will implement to support overburdened national and state healthcare systems through the donation of personal protective equipment, medicines and providing meals for front-line workers and the needy.

In addition, the promoter Desh Bandhu Gupta family has committed a sum of Rs 10 crore for other direct impact initiatives in India and elsewhere in the world to supplement Lupin's relief efforts to tackle the COVID-19 crisis.

"As one of the leading pharmaceutical companies globally, Lupin remains committed to ensure uninterrupted supply of medicines across India and global markets while ensuring safety of our personnel involved," said Managing Director Nilesh Gupta.

"We are grateful for this opportunity to support those who are at the front-line of this battle against COVID-19," he said in a statement.

Lupin is an innovation-led transnational pharmaceutical company which develops and commercialises a wide range of branded and generic formulations, biotechnology products and active pharma ingredients in over 100 markets in the United States, India, South Africa and across Asia Pacific, Latin America, Europe, and Middle East regions.

Lupin is the third-largest pharmaceutical company in the United States by prescriptions and in India by global revenues. It has a leadership position in the cardiovascular, anti-diabetic and respiratory segments besides a significant presence in the anti-infective, gastro-intestinal, central nervous system and women's health areas.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 11 2020 | 10:39 AM IST

Next Story